Scholarlink

<p>Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has achieved notable efficacy in relapsed/refractory multiple myeloma (RRMM), yet most patients eventually relapse, highlighting the need to elucidate mechanisms of resistance. In this study, we investigated the role of TIGIT in resistance to BCMA-CAR-T therapy. Tumor-infiltrating T cells from RRMM patients receiving BCMA-CAR-T therapy were analyzed by single-cell RNA sequencing, and immune checkpoint expression was further assessed by flow cytometry. Functional assays, including luciferase-based cytotoxicity, CD107a degranulation, CFSE proliferation, and CD45RO/CD62L phenotyping, were performed to investigate the effects of TIGIT inhibition through knockout or anti-TIGIT monoclonal antibodies (mAbs). In a humanized immune cell-reconstituted mouse model, TIGIT blockade was further evaluated for its effects on tumor growth and T cell exhaustion. T cells from patients with early relapse exhibited higher TIGIT expression than those from patients with durable responses, and elevated TIGIT levels were correlated with increased tumor burden and poor prognosis. While TIGIT blockade exerted limited effects on CAR-T function in vitro, it markedly enhanced CAR-T proliferation, mitigated T cell exhaustion, and improved antitumor efficacy in vivo, particularly when mediated by anti-TIGIT mAbs. Transcriptomic profiling further revealed that TIGIT modulates CAR-T activity by regulating cytokines and chemokines pathways and T cell activation, findings that were preliminarily validated by functional assays. Collectively, these findings identify TIGIT as a critical regulator of resistance to BCMA-CAR-T therapy and highlight TIGIT blockade as a promising strategy to enhance CAR-T efficacy and overcome relapse in multiple myeloma.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月19日

查看全文
  • Yuan Xia,
  • Jianfeng Zhu,
  • Rui Guo,
  • Xuxing Shen,
  • Min Shi,
  • Na Shen,
  • Lei Fan,
  • Lijuan Chen

摘要

Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has achieved notable efficacy in relapsed/refractory multiple myeloma (RRMM), yet most patients eventually relapse, highlighting the need to elucidate mechanisms of resistance. In this study, we investigated the role of TIGIT in resistance to BCMA-CAR-T therapy. Tumor-infiltrating T cells from RRMM patients receiving BCMA-CAR-T therapy were analyzed by single-cell RNA sequencing, and immune checkpoint expression was further assessed by flow cytometry. Functional assays, including luciferase-based cytotoxicity, CD107a degranulation, CFSE proliferation, and CD45RO/CD62L phenotyping, were performed to investigate the effects of TIGIT inhibition through knockout or anti-TIGIT monoclonal antibodies (mAbs). In a humanized immune cell-reconstituted mouse model, TIGIT blockade was further evaluated for its effects on tumor growth and T cell exhaustion. T cells from patients with early relapse exhibited higher TIGIT expression than those from patients with durable responses, and elevated TIGIT levels were correlated with increased tumor burden and poor prognosis. While TIGIT blockade exerted limited effects on CAR-T function in vitro, it markedly enhanced CAR-T proliferation, mitigated T cell exhaustion, and improved antitumor efficacy in vivo, particularly when mediated by anti-TIGIT mAbs. Transcriptomic profiling further revealed that TIGIT modulates CAR-T activity by regulating cytokines and chemokines pathways and T cell activation, findings that were preliminarily validated by functional assays. Collectively, these findings identify TIGIT as a critical regulator of resistance to BCMA-CAR-T therapy and highlight TIGIT blockade as a promising strategy to enhance CAR-T efficacy and overcome relapse in multiple myeloma.